DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for mucopolysaccharidosis type 7 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMucopolysaccharidosis type 7 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mucopolysaccharidosis type 7 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glucuronidase beta (GUSB) — GUSB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3HN3 · 1.7 Å · ligand (4R)-2-METHYLPENTANE-2,4-DIOL (MRD). Experimental structure, not a prediction.
What the evidence adds up to
The MPS I Registry analysed 987 untreated patients, of whom 60.9% had the severe Hurler phenotype, 23.0% had Hurler-Scheie, and 12.9% had Scheie. Median age at symptom onset ranged from 6 months (Hurler) to 5.3 years (Scheie), but median age at treatment initiation was 1.5 years for Hurler, 8.0 years for Hurler-Scheie, and 16.9 years for Scheie, confirming a substantial diagnostic delay in attenuated forms. Coarse facial features and corneal clouding were the most common symptoms across all phenotypes. A separate case report describes a child with typical signs from early infancy who was diagnosed only at 22 months and was about to start enzyme replacement therapy; the authors state that earlier detection leads to better and more effective treatment, with options being enzyme replacement or haematopoietic stem cell transplantation.
A review of modern management in children covers epidemiology, pathogenesis, classification, and evidence-based diagnosis including differential diagnosis, and devotes attention to pathogenetic, symptomatic, and surgical treatment. Another paper lists current challenges: the need for adequate classification linked to therapeutic indications; early diagnosis via neonatal screening, including its advantages and barriers; spinal and eye disease care from diagnosis through follow-up and treatment; allergic reactions caused by enzyme replacement therapy; and transition to adult care. A case report from Bangladesh notes that limited diagnostic facilities impede therapeutic approaches for mucopolysaccharidosis in that country.
No abstract reports a controlled trial of any drug for MPS I, nor provides survival or response rates. The only treatments mentioned are enzyme replacement therapy and haematopoietic stem cell transplantation, both described as existing options rather than subjects of new evidence. What remains missing is prospective data on long-term outcomes of these treatments in well-characterised cohorts, standardised protocols for managing allergic reactions, validated neonatal screening programmes in low-resource settings, and any trial of a repurposed drug for MPS I.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Genetics in Medicine · 2014 · 173 citations · open access
The natural history of MPS I: global perspectives from the MPS I Registry
AbstractPURPOSE: In this study, we aimed to describe the natural history of mucopolysaccharidosis I. METHODS: Data from 1,046 patients who enrolled in the MPS I Registry as of August 2013 were available for descriptive analysis. Only data from untreated patients and data prior to treatment for patients who received treatment were considered. Age at symptom onset, diagnosis, and treatment initiation were examined by geographic region and phenotype (from most to least severe: Hurler, Hurler-Scheie, and Scheie). For each symptom, frequency and age at onset were examined. RESULTS: Natural history data were available for 987 patients. Most patients were from Europe (45.5%), followed by North America (34.8%), Latin America (17.3%), and Asia Pacific (2.4%). Phenotype distribution was 60.9% for Hurler, 23.0% for Hurler-Scheie, and 12.9% for Scheie (3.2% undetermined) syndromes. Median age at symptom onset for Hurler, Hurler-Scheie, and Scheie syndromes was 6 months, 1.5 years, and 5.3 years, respectively; median age at treatment initiation was 1.5 years, 8.0 years, and 16.9 years, respectively. Coarse facial features and corneal clouding were among the most common symptoms in all three phenotypes. CONCLUSION: A delay between symptom onset and treatment exists, especially in patients with attenuated mucopolysaccharidosis I. A better understanding of disease manifestations may help facilitate prompt diagnosis and treatment and improve patient outcomes.
Педиатрическая фармакология · 2022 · 2 citations · open access
Modern Approaches to the Management of Children with Mucopolysaccharidosis Type I
AbstractThis article presents modern data on epidemiology, etiology, and clinical manifestations of mucopolysaccharidosis (MPS) type I in children. MPS develops due to deficiency of particular lysosomal enzyme which determines the disease type. The article considers in details disease's pathogenesis and classification. Evidence-based approaches to diagnosis (differential diagnosis included) are covered, moreover, special attention is paid to pathogenetic, symptomatic, and surgical treatment of MPS.
Residência Pediátrica · 2021 · 0 citations · open access
Hurler syndrome: diagnostic journey in an orphan disease - case report
AbstractOBJECTIVES: Promote the early detection of the disease through pertinent clinical findings in patients with mucopolysaccharidosis. CASE REPORT: Patient with MPS I with typical clinical signs of the disease from a very early age were diagnosed only at 22 months old and will begin enzymatic replacement therapy. DISCUSSION: The disease, the earlier it is detected, the better and more effective the treatment, which may be enzyme replacement therapy, or, in the last case, transplantation of hematopoietic stem cells.
Archivos Argentinos de Pediatria · 2021 · 0 citations · open access
Algunos desafíos en mucopolisacaridosis tipo I
AbstractHere we describe the current challenges of mucopolysaccharidosis type I: the need for an adequate classification, establishing its relationship to therapeutic indications; an early diagnosis, from neonatal screening, its advantages and barriers, to clinical suspicion of severe and attenuated forms; spinal and eye disease care, from diagnosis to follow-up and treatment; allergic reactions caused by enzyme replacement therapy, their diagnosis and treatment. And lastly, transition to adult care.
INDIGO (University of Illinois at Chicago) · 2022 · 0 citations · open access
sj-pdf-1-imr-10.1177_03000605221106412 - Supplemental material for Limited diagnostic facilities impeding the therapeutic approach of Mucopolysaccharidosis in Bangladesh: a case report
AbstractSupplemental material, sj-pdf-1-imr-10.1177_03000605221106412 for Limited diagnostic facilities impeding the therapeutic approach of Mucopolysaccharidosis in Bangladesh: a case report by Orindom Shing Pulock, Susmita Dey Pinky and Syeda Humaida Hasan in Journal of International Medical Research
Sage Journals Data · 2022 · 0 citations · open access
sj-pdf-1-imr-10.1177_03000605221106412 - Supplemental material for Limited diagnostic facilities impeding the therapeutic approach of Mucopolysaccharidosis in Bangladesh: a case report
AbstractSupplemental material, sj-pdf-1-imr-10.1177_03000605221106412 for Limited diagnostic facilities impeding the therapeutic approach of Mucopolysaccharidosis in Bangladesh: a case report by Orindom Shing Pulock, Susmita Dey Pinky and Syeda Humaida Hasan in Journal of International Medical Research
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
